- Home
- EDRY vs CGTX Comparison
EDRY vs CGTX Comparison
Compare EDRY & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDRY | CGTX |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EDRY | CGTX |
|---|---|---|
| Price | $13.00 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | 3.1K | ★ 926.7K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,384,447.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.60 | $0.22 |
| 52 Week High | $16.14 | $3.83 |
Technical Indicators
Market Signals| Indicator | EDRY | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.50 | 41.98 |
| Support Level | $12.94 | $1.44 |
| Resistance Level | $13.75 | $1.62 |
| Average True Range (ATR) | 0.26 | 0.11 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 40.00 | 17.03 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.